To appraise the clinical and cost effectiveness of depatuxizumab mafodotin within its marketing authorisation for treating recurrent EGFR-amplified glioblastoma.
Status Proposed
Process STA
ID number 1244

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
25 September 2017 - 23 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
20 October 2017 Please note this scoping exercise has now been suspended pending confirmation of trial reporting and regulatory submission timelines. Please do not submit comments on this topic. We apologise for any inconvenience this may cause.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance